Context: Two reports suggested that vitamin D 2 is less effective than vitamin D 3 in maintaining vitamin D status.
V
itamin D 2 , which comes from the UV irradiation of ergosterol obtained from yeast, has been the mainstay for the prevention and treatment of vitamin D deficiency in children and adults for more than 80 yr (1, 2) . As little as 100 IU vitamin D 2 was found to be effective in the prevention of rickets (2) (3) (4) . When humans are exposed to sunlight, 7-dehydrocholesterol in the skin absorbs UVB (290 -315 nm) radiation resulting in the production of vitamin D 3 (1, 3) . Vitamin D 3 is found naturally in cod liver oil and oily fish such as salmon (1, 3) . Vitamin D 3 is also made by irradiating 7-dehydrocholesterol obtained from lanolin from sheep's wool with UVB radiation (1) 3 are available in supplements, but only vitamin D 2 is available as a pharmaceutical preparation because its use predated the Food and Drug Administration and, thus, was grandfathered as a pharmaceutical drug. Vitamin D 3 was commercially developed in the 1950s and has not been approved as a pharmaceutical agent in the United States but is used in food supplementation and vitamin supplements.
Since 
Subjects and Methods

Subjects
Healthy, white, African-American, Hispanic, Asian, and Native American adults between the ages of 18 and 84 yr were enrolled in February 2007 after signing a consent form approved by our Institutional Review Board at Boston University Medical Center. We excluded those with chronic liver and kidney disease and those taking medications, including anticonvulsants, glucocorticoids, and barbiturates, that might affect vitamin D metabolism as well as subjects who were taking a vitamin D supplement. Subjects were permitted to take their multivitamin, a majority of which contained 400 IU vitamin D 3 (Table 1) .
Design
Sixty-eight subjects were randomly assigned in a double-blinded fashion to receive daily in a capsule for 11 wk 1) placebo, 2) 1000 IU (25 g) vitamin D 2 (ergocalciferol), 3) 1000 IU (25 g) vitamin D 3 (cholecalciferol), or 4) 500 IU vitamin D 2 plus 500 IU vitamin D 3 . All of the capsules made by Tishcon Corp. (Salisbury, MD) contained lactose (98.75%), magnesium stearate (1.0%), and silicon dioxide (1.25%). All of the products were analyzed in our laboratory by HPLC and found to contain either no vitamin D (placebo) or concentrations within 10% of their specified content. All subjects had blood samples collected at baseline and every week for a total of 11 wk. Each subject was given a dietary questionnaire at baseline to assess multivitamin and milk consumption. Pill compliance (Table 1 ) was determined by a pill count at each visit.
Analytical methods
Serum 25(OH)D 2 and 25(OH)D 3 were determined by liquid chromatography tandem mass spectroscopy at Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (10). The detection limit for the assay was 4 ng/ml, and the interassay coefficient of variation was about 10%. Values for serum 25(OH)D 2 reported as less than 4 ng/ml were obtained by subtracting 25(OH)D 3 from the total 25(OH)D.
Statistical methods
The results are presented as means Ϯ SD. Data were analyzed using mixed-effects regression to perform a repeated-measures analysis of 25(OH)D levels across time and groups. Pairwise comparisons were began to plateau by wk 6 and was 28.9 Ϯ 11.0 ng/ml at the end of the study, which was not statistically different from the vitamin D 2 group (26.8 Ϯ 9.6 ng/ml) (Fig. 1) .
To determine whether vitamin D 2 ingestion had any effect on circulating levels of 25(OH)D 3 , we determined 25(OH)D 2 and 25(OH)D 3 in the samples. The 25(OH)D 2 levels increased from undetectable (Ͻ4 ng/ml) to 14 Ϯ 5.3 ng/ml by wk 6 and remained at approximately 14 ng/ml for the ensuing 5 wk in the group that received 1000 IU vitamin D 2 ( Fig. 2A) . The baseline 25(OH)D 3 level in the same subjects was 15.1 Ϯ 9.8 ng/ml and did not significantly change during the entire study and was 13.6 Ϯ 10.2 ng/ml at the end of the study (P ϭ 0.14) (Fig. 2A) . Similarly, the group that received vitamin D 3 showed no significant change in the serum 25(OH)D 2 throughout the study (P ϭ 0.33) (Fig. 2B) .
To determine further whether vitamin D 2 interfered with vitamin D 3 metabolism, we gave one group of subjects 500 IU vitamin D 2 mixed with 500 IU vitamin D 3 daily, and the total 25(OH)D levels at the end of the study were no different in all three groups (P ϭ 0.957) (Fig. 1 ). An analysis of the 25(OH)D 2 and 25(OH)D 3 also demonstrated a comparable increase in both levels in the group that received the combination of 500 IU vitamin D 2 (5.7 Ϯ 4.5 ng/ml) and 500 IU vitamin D 3 (6.1 Ϯ 4.3 ng/ml) (Fig. 2C) .
Discussion
Many multivitamin preparations and some foods are fortified with vitamin D 2 . Two recent observations have raised questions as to whether vitamin D 2 should be used either as a pharmaceutical agent or as a supplement because it appeared that vitamin D 2 not only was less effective than vitamin D 3 in maintaining 25(OH)D levels (8, 9) but that it also had a negative effect on 25(OH)D status (9) . There has also been concern that vitamin D 2 may not be bioequivalent to vitamin D 3 in maintaining bone health (11) .
The Food and Nutrition Board has recommended that adults up to the age of 50 yr require 200 IU vitamin D/d, whereas adults 51-70 yr and 71 yr and older require 400 and 600 IU/d, respectively (12) . However, many experts now agree that in the absence of adequate sun exposure, at least 1000 IU vitamin D/d is required to maintain 25(OH)D in the sufficient range (1, 13) .
Because the placebo group did not demonstrate any change in their circulating levels of 25(OH)D, there was little influence of environmental sun exposure or dietary or supplemental vitamin D intake on their vitamin D status. Subjects who received 1000 IU vitamin D 2 or 1000 IU vitamin D 3 daily gradually increased blood levels of 25(OH)D to the same levels throughout the study. The increase from baseline in the total 25(OH)D levels at the end of the study was 9.3 ng/ml for the vitamin D 3 group, 9.9 ng/ml for the vitamin D 2 group, and 8.2 ng/ml for the vitamin D 2 plus vitamin D 3 group, which is consistent with the observation that serum 25(OH)D levels increased by 1 ng/ml for every 100 IU vitamin D 3 (14) . However, the 25(OH)D levels did not rise above 30 ng/ml, which is now considered to be the vitamin D-sufficient range, suggesting that more than 1000 IU vitamin D 2 or vitamin D 3 is necessary to maintain serum 25(OH)D levels above 30 ng/ml when the sun provides no vitamin D 3 .
Armas et al. (9) reported that a single dose of 50,000 IU vitamin D 2 was less effective than 50,000 IU vitamin D 3 in maintaining serum 25(OH)D levels over the ensuing 30 d in the summer. Furthermore, when compared with the group that received placebo, the group that received 50,000 IU vitamin D 2 had a significant reduction in serum 25(OH)D at the end of the study. We did not observe any negative influence of vitamin D 2 on either total 25(OH)D or 25(OH)D 3 levels ( Figs. 1 and 2 ). The maintenance of the serum 25(OH)D 3 levels observed in this report ( Fig. 1) (Fig. 1) . Furthermore, the group that received 1000 IU vitamin D 2 (19, 20) and improving bone health (16) . More studies are needed to determine whether the carrier (i.e. ethanol vs. oil vs. lactose) that vitamin D 2 and vitamin D 3 are dissolved in influence either their bioavailability or catabolism. Our observations also suggest that 1000 IU vitamin D 2 or vitamin D 3 is required to sustain blood levels of 25(OH)D above a mean of 20 ng/ml but was insufficient in raising the levels above a mean of 30 ng/ml.
